Vaccine and Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Road, Saskatoon S7N 5E3, Canada.
Vaccine. 2010 Dec 6;28(52):8306-14. doi: 10.1016/j.vaccine.2010.09.080. Epub 2010 Oct 29.
We generated poly[di(carboxylatophenoxy)-phosphazene] (PCPP) microparticles encapsulating ovalbumin (OVA) and CpG of 0.5-2.5 μm in diameter with an encapsulation efficiency of approximately 63% and 95% respectively. In mice the microparticles generated high antigen-specific IgG, IgG1 and IgG2a titers with higher IgG2a/IgG1 ratios. Whole body in vivo imaging of mice subcutaneously injected with MPs showed several fold increase of OVA and CpG in draining inguinal lymph nodes compared to soluble formulations. We conclude that PCPP MPs are more effective in enhancing immune responses compared to soluble formulations, due to co-delivery of OVA and CpG resulting in a Th1 type of immune response.
我们制备了包载卵清蛋白（OVA）和 CpG 的聚[二（羧基苯氧基）-磷杂环戊二烯]（PCPP）微球，粒径为 0.5-2.5μm，包封效率分别约为 63%和 95%。在小鼠体内，微球诱导了高抗原特异性 IgG、IgG1 和 IgG2a 滴度，且 IgG2a/IgG1 比值更高。与溶液制剂相比，皮下注射 MPs 的小鼠的全身活体成像显示，引流腹股沟淋巴结中的 OVA 和 CpG 增加了数倍。我们得出结论，与溶液制剂相比，PCPP 微球更能有效增强免疫反应，这是由于 OVA 和 CpG 的共递送导致了 Th1 型免疫反应。
